Memantine/donepezil explained

Type:	combo
Component1:	Memantine
Class1:	NMDA receptor antagonist
Component2:	Donepezil
Class2:	Acetylcholinesterase inhibitor
Tradename:	Namzaric
Dailymedid:	Memantine and donepezil
Routes Of Administration:	By mouth
Atc Prefix:	N06
Atc Suffix:	DA52
Legal Us:	Rx-only
Legal Us Comment:	^[1]
Legal Status:	Rx-only^[2]
Kegg:	D11387

Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. It is taken by mouth.

Memantine/donepezil was approved for medical use in the United States in 2014.^[3]

Further reading

• Calhoun A, King C, Khoury R, Grossberg GT . An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease . Expert Opinion on Pharmacotherapy . 19 . 15 . 1711–1717 . October 2018 . 30244611 . 10.1080/14656566.2018.1519022 . 52336224 .

Notes and References

1. Web site: Namzaric- memantine hydrochloride and donepezil hydrochloride capsule; Namzaric- memantine hydrochloride and donepezil hydrochloride kit . DailyMed . 22 January 2019 . 22 December 2023 . 20 January 2022 . https://web.archive.org/web/20220120050522/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90fedc32-19e5-480c-afc6-f35a5cf4b9aa . live .
2. Web site: Periodic safety update report single assessment donepezil / memantine . European Medicines Agency . 7 March 2024 . 2 May 2024.
3. Web site: Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules . U.S. Food and Drug Administration (FDA) . 13 May 2015 . 22 December 2023 . 22 December 2023 . https://web.archive.org/web/20231222203410/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000TOC.cfm . live .